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Even though Delta-9-tetrahydrocannabinol (THC) is a psychoactive substance, studies indicate that it has 
therapeutic properties. Moreover, the modification in Greece legislation regarding the legalization of cannabis 
has resulted in new business opportunities for medical-cannabis related companies. This study aimed to 
evaluate whether different greenhouse cover materials affect THC yield and propose a business plan for any 
potential medical-cannabis related company in Greece. A greenhouse experiment was conducted in order to 
evaluate the effect of different plastic cover films in greenhouses for the cultivation of Cannabis sativa. 
Furthermore, the economic viability of a potential medical-cannabis related business in Greece was evaluated 
based upon a financial analysis. Yields were increased in greenhouses with double plastic cover materials 
(compared to the control). According to the results of our comparative economic analysis the production of 
medical cannabis in greenhouses constructed with double layered cover materials would significantly increase 
profits. Finally, greenhouse medical-cannabis production is much promising in Greece. Nevertheless, the use of 
appropriate greenhouse cover materials should be considered as they affect THC yield and therefore, the profit 
of the company. 
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INTRODUCTION 
Cannabis (Cannabis sativa L.) is an annual, dioecious plant. It is estimated that 
cannabis has been used by man ever since 10,000 B.C. (Schultes et al., 1974; 
Merlin, 2003). The relatively high adaptability of the plant, as well as its multiple 
applications in medicine and textile production, resulted to its worldwide 
adaptation (Fleming, M. P., & Clarke, R. C.,1998, Hartsel et al., 2016). In Greece, 
hemp (cannabis) has been used in cord and fabric production for milenia, as it was 
mentioned by Herodotus (450 B.C.) (Grimmer,2013). A wide variety of chemically 
active compounds (such as cannabinoids, terpenoids, flavonoids, and alkaloids) 
are biosynthesized in cannabis (Andre et al., 2016). Out of all these different 
compounds, the cannabinoids, which are biosynthesized in the glandular 
trichomes of the plant, are most prominently studied substances of cannabis 
(Taura et al., 2007; Brenneisen, 2007). Even though more than 100 cannabinoids 
have been identified, Δ-9-tetrahydrocannabinol (Δ9 -THC) and cannabidiol (CBD) 
are widely accepted as the most important ones due to their pharmacologic 
properties (Sikora et al., 2011). In fact, although THC is the major psychoactive 
ingredient of cannabis, medical cannabis is characterized by a high THC content, 
in contrast to industrial cannabis (hemp) (Whiting et al., 2015). Nowadays, the 
global market for medical cannabis is estimated to reach $55.8 billion by 2025, 
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with a Compound Annual Growth Rate (CAGR) of 17.10%, between 2015-2025.  
In Greece the interest regarding cannabis production has been renewed (Folina et al., 2019). Recent legislation 
changes (passed on the 24th of May, 2021), authorize the production, possession, storage, transport and supply of 
propagating material, raw materials, and substances of Cannabis sativa L. containing more than 0.2% 
tetrahydrocannabinol (THC). Moreover, the installation and operation of a processing plant for the production of 
final medical cannabis products for the purpose of either direct disposal in pharmacies, drugstores, clinics, private 
clinics, public hospitals or the export in the form of dried flower packing up to thirty (30) grams for medical and 
pharmaceutical purposes only is also permitted. It should also be mentioned that the cultivation of cannabis for 
medical use is allowed only indoors and with 24-hour guarding operation (Hellenic Republic, 2021).   
The aim of the present study was to evaluate the potential profitability of a company with THC-based products 
in order to perform this evaluation the yield from three different greenhouses was assessed and a 5-year business 
plan was formed based on the yield reported in the greenhouse that performed the best. 
 
MATERIALS AND METHODS 
Study area 
  A greenhouse pot experiment was conducted in the Agricultureal University of Athens (37°98′N, 23°70′E) from 
the 1st of March to the 27th of May, 2021. The cannabis variety used in the present study was Futura 75. Although 
this variety has a low THC content and is mainly intended for industrial use, its agronomic traits and greenhouse 
performance are similar to medical varieties. The experiment was carried out in 3 greenhouses constructed with 
different polyethylene cover films. One of these greenhouses (the control) was constructed with a single layered 
film, while the other two were constructed with double layered films. The films used in each greenhouse are 
presented on Table 1.  
 
Table 1. The 3 different types of films that were used in each greenhouse 
GREENHOUSE INSIDE OUTSIDE 
 1 EVO2 7804 AC EVO2 7804 AC 
2 (CONTROL) EVO 7551 AC  
3 EVO 7551 AC UV 2906 
 
A total of 120 16-litre pots, filled with a mixture of soil from the experimental field of the Laboratory of 
Agronomy, and compost (1:1 v/v) were placed in each greenhouse. Additionally, the plants were irrigated 2-3 times 
per week via a drip irrigation system installed in each greenhouse. 
All the greenhouses were equipped with blackout curtains which helped to initiate the flowering of cannabis. In 
order to do so, a blackout protocol (12 hours day and 12 hours night) was applied for three weeks. Finally, no 
pesticides or any other agrochemicals were applied during the growing season (from sowing to harvest). Shortly 
before the end of the experiment, 10 plant samples were taken from each greenhouse in order to estimate the 
average number of buds and their weight.  
5-year business plan 
A 5-year business plan was also formed for the establishment of a vertically integrated processing plant for end-
products of medical cannabis, covering an area of 16,000 m2, of which 10,000 m2 were for greenhouses without the 
aisles. The licensing and operation of the processing plant will be in accordance with the law provisions regarding 
final products of medical cannabis (Hellenic Republic, 2018; Hellenic Republic, 2021). The investment result in the 
production of the following final cannabis products of the species Cannabis sativa L., with a tetrahydrocannabinol 
(THC) content of more than 0,2 %. The THC content was lab estimated according to the method developed by the 
Pesticide Metabolomics Group (Kostopoulou et al., 2020): 
- Packaged dry inflorescence in packages of 1 gram. 
- Bottled Cannabis Oil (THC Oil) in 10 ml packages. 
The production capacity of the plant is 4.000 kg of dry inflorescence and 320,16 liters of cannabis oil per year.  
The total budget of this investment project is 10.586.758,77 € and this cost can be covered to a certain extent 
by own funds (approximately. 20%) and by lending at a very low interest rate (3%) as well as by a subvention of 
more than 20% of the final budget (Table 2). The total budget was distributed amongst the building installation and 
the operating expenses of the 1st year. Following the 1st year of operation, the production costs of each year were 
covered by the net profit of the previous year.   
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Table 2. The sources of business financing 
FUNDING SCHEME AMOUNT (€) PERCENTAGE 
OWN FUNDS 2.313.030,77 22% 
LENDING 6.080.148,00 57% 
SUBVENTION 2.193.580,00 21% 
TOTAL 10.586.758,77 100% 
 
RESULTS AND DISCUSSIONS 
Results indicate that the average number of buds per plant, as well as their weight, in greenhouses with double 
plastic cover materials were increased compared to the control, (Figures 1 and 2). The average bud weight was 
significantly increased in the 3rd greenhouse, compared to the 1st one (Figure 1). On the contrary, the average 
number of buds in the 1st and 3rd greenhouse did not report any statistically significant differences (Figure 2). Thus, 
the highest yields and the best performance were reported in the 3rd greenhouse.  
 
  
Figure 1. Mean inflorescence weight in 3 
greenhouses 
Figure 2. Number of buds per plant in 3 greenhouses 
 
Based on the results of the 3rd greenhouse, a 5-year business plan was formed and presented on Tables 3, 4, 5, 
and 6. 
Table 3. Annual value of sales 
PRICE 
UNIT 





9.200.000 € 9.200.000 € 9.200.000 € 9.200.000 € 9.200.000 € 67% 
14.000 € THC Oil(L) 4.482.240 € 4.482.240 € 4.482.240 € 4.482.240 € 4.482.240 € 33% 
 TOTAL 13.682.240 € 13.682.240 € 13.682.240 € 13.682.240 € 13.682.240 € 100% 
  
As can be seen from Table 3, the total annual value of sales amounts to 13.682.240 € and is constant for all the 
years of the business operation. 
Table 4. The production cost of the company’s product 
PRODUCTION COST YEAR 1 YEAR 2 YEAR 3 YEAR 4 YEAR 5 
THC Oil  (€/L) 5.240,19 € 5.126,29 € 5.012,39 € 4.898,49 € 4.784,59 € 
Dry Inflorescence 
(€/kg)  
851,56 € 833,05 € 814,54 € 796,03 € 777,52 € 
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Table 5. Net Profit and the business owner income during the first 5 years of operation 
 
It’s easy to understand that this investment is worthwhile due to the high Net Present Value and IRR (Internal 
Rate of Return) of up to 80%. While its net profit can reach 9.040.318 € after 5 years of operation. (Table 5 and 
Table 6). 
Table 6. Net Present Value and Internal Rate of Return 
NPV/ IRR 
NPV 32.054.375,27 € 
IRR 80% 
 
 Double cover films have a positive impact on the yield of cannabis. Therefore, in order to maximize the yield, 
their properties should be taken into account. Furthermore, the establishment of a vertically integrated processing 
plant for medical cannabis products that uses such cover films can generate a very good income for the business 
owner. The entrepreneur's income could reach up to 9,778,223 € after 5 years of operation of the unit. The modern 
equipment and facilities, the controlled production process throughout the year, the high subsidy on the initial 
investment cost and the great demand that will arise in the near future for the specific products, are some of the key 
factors that ensure the business viability. This industry will be widely recognized due to both the more favorable 
legal framework and the recognition of the benefits of cannabis products. In addition, a very important factor in 
ensuring the viability of this type of business is the weak competition that prevails in this sector.  
 
CONCLUSIONS 
In conclusion, the financial results (Net Profit, Entrepreneur’s Income,) that resulted from the financial analysis, 
as well as the economic indicators of Net Present Value and Internal Rate of Return, suggest that the establishment 
of a vertically integrated processing plant for medical cannabis products is a profitable investment. It is a project 
that not only can provide a very good income to the owner of the business, but in the long run can contribute to the 
economic development of Greece and its international recognition, since Greece with minor exceptions has all the 
specifications and prerequisites for the orderly operation of such businesses. 
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